Cardinal Health (CAH): Deep Value to Peak Optimism

Introduction

Cardinal Health closed at $236.02 on September 10, 2026 — inside 5% of its 52-week (and all-time) high of $247.18, hit nine trading days earlier (SPXScore trailing-data tracking). By almost any plain-English reading, that isn't what a "buy the dip" opportunity looks like. Yet the Opportunity Score on Cardinal Health's SPXScore page reads high and sits inside a historically favorable window right now — the exact combination the site flags as worth a second look.

Both are true at once, and reconciling them is the point of this piece. Pull CAH's trailing valuation across the last six years, and the shape isn't a single re-rating from cheap to expensive. It's a genuine deep-value entry, a two-year earnings crater caused by a real legal bill, an "air pocket" where the trailing P/E stopped meaning much of anything, and a recovery that has pushed the stock to record highs on a growth rate that's partly a mathematical artifact. Untangling which parts of today's "buy" signal reflect the business getting genuinely better, and which are an accounting quirk, is what a $266 average price target and a 100-reading opportunity gauge can't tell you on their own.

Key Takeaways

• CAH's trailing P/E averaged 16.4x in 2021, jumped to 24.8x in 2022 as an opioid-settlement charge cratered EPS (not because price ran up), blew out to a 76.5x "air pocket" average in 2023 as trailing EPS neared zero, then settled near 32.2x year-to-date in 2026 (SPXScore trailing-data tracking).
• The site's full-history Opportunity Score reads just 29.1 as of Sept. 10, 2026 — "Neutral" under its own bands (weak ≤25, strong ≥55) — even though the six-month-rescaled figure shown by default on the trends page reads 100, purely because CAH's own recent range has been narrow and weak.
• Trailing PEG has collapsed to 0.35 — but that's arithmetic on a 93.6% three-year compound annual EPS growth rate (CAGR) measured against fiscal 2023's settlement-crushed base of $1.00 a share, not repeatable growth; FY2027 guidance calls for a far more modest 13–15% non-GAAP EPS growth.
• Q4 FY2026 results (Aug. 11) showed revenue of $63.7 billion (+6%) and GAAP EPS of $1.70 (+70% YoY) — but roughly $100 million of that quarter's medical-products profit came from a one-time tariff refund tied to a February 2026 Supreme Court ruling, not organic improvement (Cardinal Health Q4 FY2026 results).
• Wall Street's consensus is Moderate Buy — 16 buy, 3 hold, 0 sell, average target $266.56 (~13% upside from CAH's $236.02 close) — with Morgan Stanley, Wells Fargo, and Barclays all raising targets to $265–$277 right after earnings (MarketBeat; GuruFocus).

A Multiple That Tells Five Different Stories

Period	Avg. trailing P/E	Trailing EPS, start → end	Price range	Avg. Opportunity Score
2021	16.4x	$3.31 → $3.87	$46.23 – $62.28	25.8
2022	24.8x	$3.87 → -$3.99	$50.75 – $80.11	21.7
2023	76.5x	-$3.99 → $0.81	$70.72 – $107.93	6.4
2024	46.4x	$0.81 → $5.14	$94.75 – $123.51	18.0
2025	25.9x	$5.14 → $6.63	$121.40 – $213.73	15.8
2026 YTD	32.2x	$6.63 → $7.24	$182.56 – $247.18	11.4

Source: SPXScore trailing-data tracking, weekly observations, 2021–2026. See how the same framework reads across other names in the S&P 500 coverage, including the free S&P 50 subset, or compare a similar deep-value-to-peak-optimism arc in Home Depot's multiple history.

2021: A Genuinely Cheap Stock, Before the Bill Arrived

Cardinal Health entered 2021 trading at a trailing P/E that averaged 16.4x, ranging as low as 11.1x, on a price band of $46.23 to $62.28 and trailing EPS climbing from $3.31 to $3.87 (SPXScore trailing-data tracking). That's a legitimately inexpensive multiple for a company running $180 billion-plus in annual revenue through drug distribution, and it reflected a real overhang. Cardinal Health, with two other national distributors, had reached a nationwide settlement over its role in the opioid crisis, and the market was discounting the stock for a liability whose size wasn't yet fully known.

2022: The Charge Hits, and the Trailing Multiple Lies About It

That liability arrived on the income statement in the quarter ended March 31, 2022. Cardinal Health booked a settlement-related charge that pushed quarterly EPS to a loss of $5.06 a share, dragging full fiscal-2022 GAAP EPS to a loss of $3.34 (SPXScore trailing-data tracking). The stock itself didn't collapse — price climbed from $52.71 to $76.73 across the calendar year, as the market treated the charge as one-time rather than open-ended. But trailing P/E runs off trailing earnings, and trailing earnings had just gone deeply negative. So the reported multiple did something backwards. It spiked to an average of 24.8x, higher than 2021's level, purely because the denominator had cratered — a headline multiple that looked more expensive exactly when the underlying business was getting cheaper.

2023: The Air Pocket

By 2023, trailing EPS was still working back from the charge — starting the year at a loss of $3.99 and finishing at a positive $0.81. The resulting trailing P/E spent the year in a range that stopped carrying much information: an average of 76.5x, spiking as high as 133x, on a price band of $70.72 to $107.93 (SPXScore trailing-data tracking). The stock kept climbing regardless, evidence the market was already looking past the accounting noise to the cash-generating business underneath. But it's exactly the kind of stretch where a naive "P/E is high, so the stock is expensive" read would have been badly wrong. It's also where the Opportunity Score's valuation component, dependent on a clean trailing PEG, had nothing usable to work with at all.

2024–2025: The Rebuild, on Real Growth This Time

The recovery in 2024 and 2025 was built on more durable ground. Cardinal Health's specialty pharmaceutical distribution business — GLP-1 diabetes and weight-loss drug volumes, biosimilar adoption, and newly acquired oncology and infusion physician networks — became the company's clearest growth engine, with specialty revenue tracking toward more than $50 billion in fiscal 2026 on roughly a 16% three-year compound growth rate (Morningstar).

Trailing EPS climbed from $0.81 to $5.14 across 2024 and on to $6.63 by the end of 2025. Trailing P/E stayed elevated off the low base in 2024, averaging 46.4x, then settled to a more ordinary-looking 25.9x average in 2025 as earnings caught up to a price that nearly doubled, from $121.40 to $213.73, over the year (SPXScore trailing-data tracking).

2026: Priced Near a Record High, on a Growth Rate That Won't Repeat

Which brings the story to today. Fourth-quarter fiscal 2026 results, reported August 11, showed $63.7 billion in quarterly revenue (up 6%) and GAAP diluted EPS of $1.70, up 70% year over year. Full fiscal-2026 GAAP EPS reached $7.23, up 12%, with non-GAAP EPS of $11.26, up 37% (Cardinal Health Q4 FY2026 results, Aug. 11, 2026).

Roughly $100 million of the medical-products segment's quarterly profit, though, came from a one-time IEEPA tariff refund tied to a February 2026 Supreme Court ruling — a real but non-repeating item Yahoo Finance flagged as inflating the headline beat (Yahoo Finance).

That $7.23–$7.24 trailing EPS is also the number behind CAH's now-startling 0.35 trailing PEG, well under the 0.4 floor where the Opportunity Score's valuation component maxes out. Comparing fiscal 2026's $7.23 against fiscal 2023's settlement-crushed $1.00 produces a three-year EPS CAGR above 90%. That's an accurate calculation, and a genuinely misleading one. It measures the bounce off a legal-charge trough, not a repeatable trajectory. Fiscal 2027 guidance calls for a far more modest 13–15% non-GAAP EPS growth, to $12.40–$12.60 a share, with 3–5% pharma revenue growth (new IRA drug-pricing rules cited as a headwind) and 11–13% growth in the smaller at-Home Solutions business.

What the Opportunity Score Is Actually Measuring Right Now

Here's the reconciliation promised at the top. The Opportunity Score weights a 52-week drawdown at 80% and trailing PEG at 20%, then applies a recovery-momentum multiplier. It's a design the site's own methodology notes describe as having, at best, "weak evidence with a roughly 1-year horizon," not a long-range call (SPXScore methodology). At $236.02, CAH sits only 4.5% below its 52-week high, so the drawdown component, the score's dominant input, contributes almost nothing (9 out of 100).

What's pushing the headline number up is the six-month rescaled version shown by default on the trends page. It stretches the latest reading against only CAH's own trailing six months, and that week happens to be the best week in a narrow, generally weak window. So it rescales to a perfect 100, regardless of how attractive it is against the tool's full history.

Judged against the whole tracked record, CAH's score reads 29.1 on this single day. That's well above the 11.4 average for 2026 year-to-date shown in the chart above, since the score has been climbing through the summer. It's still "Neutral," though, short of the 55 threshold for "Above average" — a level it hasn't cleared in any full year since 2021.

The site's separate "favorable window" indicator — built from trailing PEG and 26-week momentum — has flagged CAH favorable since August 31, driven by that same sub-0.4 PEG paired with roughly 14% trailing six-month momentum. That's a real, rules-based reading, not a fabricated one — but by construction it's a bet that a stock which has already risen keeps rising, layered on a PEG that's cheap partly because of a base-year accounting quirk.

The Macro Backdrop This Is Trading Into

Cardinal Health's re-rating is unfolding against a mixed macro picture. August's jobs report, released September 4, beat sharply — 162,000 nonfarm payrolls added against a roughly 53,000 consensus, unemployment holding at 4.1% (BLS, Sept. 4, 2026). August CPI, released September 11, held headline inflation at 3.4% year over year with core easing slightly to 2.4% (BLS, Sept. 11, 2026). The Fed's next rate decision lands September 16, still undecided as of this writing, with CME FedWatch-tracked odds of a quarter-point hike near 66% after Chair Kevin Warsh's Jackson Hole remarks were read as hawkish (CNBC, Aug. 31, 2026).

Layered on top, an escalating U.S.-Iran conflict pushed WTI crude above $102 a barrel and Brent above $107 in early September, its highest settle since May — a direct input-cost risk for a company running one of the country's largest pharmaceutical trucking and logistics networks (CNBC, Sept. 9, 2026).

Conclusion: Is This a Real Opportunity?

There's a genuine bull case. Specialty and GLP-1 distribution volumes are real, durable growth. The opioid liability is now a well-characterized, amortizing obligation, $4.3 billion accrued as of June 30, 2026, paid down in scheduled installments through 2038, rather than an open-ended unknown (Cardinal Health FY2026 10-K). And Wall Street keeps raising targets, not cutting them.

But calling today's setup "deep value" the way 2021's 16.4x multiple was would be a stretch. The stock trades within 5% of its record high, its cheapest-looking metric is an artifact of comparing this year's earnings to a litigation-crushed base year rather than evidence of accelerating growth, and the more reliable full-history Opportunity Score still reads Neutral, not Strong. What today's signal really rewards is conviction in the specialty-distribution growth story and tolerance for a multiple that's already re-rated — not the belief that the market hasn't noticed a bargain.

---

This article discusses Cardinal Health's historical stock performance and macroeconomic conditions as of September 14, 2026, for informational purposes only. It is not investment advice or a recommendation to buy or sell any security. Financial data, guidance, and analyst estimates referenced here are subject to revision by the company and by third-party research providers, and the Federal Reserve's September 16, 2026 rate decision had not yet been announced at the time of writing.